QuickView for Tiaprofenic acid (compound)

Summary
General Info

PubChem

PubChem Compound 10355289

Name:	tiaprofenic acid
PubChem Compound ID:	10355289
Molecular formula:	C₁₄H₁₂O₃S
Molecular weight:	261.315 g/mol

DrugBank

Identification

Name:	tiaprofenic acid
Name (isomeric):	DB01600
Drug Type:	small molecule
Synonyms:	Acidum tiaprofenicum [inn-latin]; 2-(5-Benzyl-2-thienyl)propionsaeure; Acido tiaprofenico [inn-spanish]; Acide tiaprofenique [inn-french]; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; Tiaprofensaeure
Brand:	Novo-Tiaprofenic, Tiaprofenic-200 - Tab, Tiaprofenic-300 - Tab, Nu-Tiaprofenic, Apo-Tiaprofenic Tablets, PMS-tiaprofenic, Surgam, Dom-tiaprofenic, Surgam SR
CAS number:	33005-95-7

Pharmacology

Indication:	Tiaprofenic acid is used to treat pain, especially arthritic pain.
Pharmacology:	Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.
Mechanism of Action:	Tiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.
Absorption:	Bioavailability is 90% following oral administration.
Biotransformation:	Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.
Half Life:	1.5-2.5 hours
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take with food.

Drug interaction:

Methotrexate	Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.
Escitalopram	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Aminosalicylic Acid	Increased risk of gastrointestinal bleeding.
Cholestyramine	The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect.
Pemetrexed	Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered.

Methotrexate	Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.
Escitalopram	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Aminosalicylic Acid	Increased risk of gastrointestinal bleeding.
Cholestyramine	The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect.
Pemetrexed	Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered.
Treprostinil	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy.
Telmisartan	Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
Fluoxetine	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Salsalate	Increased risk of gastrointestinal bleeding.
Cyclosporine	Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy.
Sertraline	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Ginseng	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
Colesevelam	The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect.
Lithium	Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed.
Timolol	The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol.
Acetylsalicylic acid	Increased risk of gastrointestinal bleeding.
Citalopram	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Paroxetine	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Acenocoumarol	Increased risk of bleeding.
Fluvoxamine	Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding.
Warfarin	The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Ginkgo biloba	Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.
Colestipol	The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect.
Ketorolac	Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity.
Trandolapril	The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.

show less «

Targets

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1